利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.028 秒)

    OXYIMINO COMPOUNDS AND THE USE THEREOF
    1.
    发明申请
    OXYIMINO COMPOUNDS AND THE USE THEREOF 有权
    OXYIMINO化合物及其用途

    公开(公告)号：US20100240703A1

    公开(公告)日：2010-09-23

    申请号：US12602441

    申请日：2008-05-30

    申请人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    发明人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    IPC分类号： A61K31/445 ,  C07D211/96 ,  A61P29/00 ,  A61P25/00 ,  A61P9/06 ,  A61P9/12 ,  G01N33/53

    CPC分类号： C07D211/96

    摘要： The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R1 and R2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及（式I）的氧亚氨基化合物及其药学上可接受的盐，前药和溶剂化物，其中：Y是CO或SOm; Z是氢，每个任选取代的低级烷基，低级烯基，芳基，杂环基等.R 1和R 2各自独立地为氢，各自为任选取代的低级烷基，低级烯基，环烷基，芳基，杂环基等，各X独立地为= 任选取代的低级烷基，氰基，硝基等，m为1或2，p为O，1或2，q为O或1.本发明还涉及式I的用途化合物，以治疗，预防或改善 对钙通道阻断，特别是N型钙通道的阻滞作用。 本发明的化合物特别适用于治疗疼痛。

    OXIME COMPOUNDS AND THE USE THEREOF
    2.
    发明申请
    OXIME COMPOUNDS AND THE USE THEREOF 审中-公开
    OXIME化合物及其用途

    公开(公告)号：US20090298878A1

    公开(公告)日：2009-12-03

    申请号：US12373328

    申请日：2007-07-12

    申请人： Akira Matsumura ,  Hidenori Mikamiyama ,  Naoki Tsuno ,  Donald J. Kyle ,  Bin Shao ,  Jiangchao Yao

    发明人： Akira Matsumura ,  Hidenori Mikamiyama ,  Naoki Tsuno ,  Donald J. Kyle ,  Bin Shao ,  Jiangchao Yao

    IPC分类号： A61K31/445 ,  C07D211/98 ,  G01N23/00 ,  C07D401/12

    CPC分类号： C07D211/72 ,  C07D211/96 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

    摘要： The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CR3R4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like; W is optionally substituted lower alkylene or optionally substituted lower alkenylene, R3 and R4 are each independently hydrogen, lower alkyl or the like; p is 0, 1, or 2 and q is 0, 1 or 2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及式（I）的肟化合物及其药学上可接受的盐，前药或溶剂化物，其中X是氢，任选取代的芳基，任选取代的杂芳基等; Y是CO，SO2，CR3R4等; Z是任选取代的低级烷基，任选取代的芳基等; W是任选取代的低级亚烷基或任选取代的低级亚烯基，R 3和R 4各自独立地是氢，低级烷基等; p是0,1或2，q是0,1或2.本发明还涉及使用式I化合物来治疗，预防或改善对阻断钙通道有响应的病症，特别是N型 钙通道。 本发明的化合物特别适用于治疗疼痛。

    Oxyimino compounds and the use thereof
    3.
    发明授权
    Oxyimino compounds and the use thereof 有权
    氧亚氨基化合物及其用途

    公开(公告)号：US08563732B2

    公开(公告)日：2013-10-22

    申请号：US12602441

    申请日：2008-05-30

    申请人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    发明人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    IPC分类号： A61K31/44 ,  C07D211/00

    CPC分类号： C07D211/96

    摘要： The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R1 and R2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及（式I）的氧亚氨基化合物及其药学上可接受的盐，前药和溶剂化物，其中：Y是CO或SOm; Z是氢，每个任选取代的低级烷基，低级烯基，芳基，杂环基等.R 1和R 2各自独立地为氢，各自为任意取代的低级烷基，低级烯基，环烷基，芳基，杂环基等，各X独立地为= 任选取代的低级烷基，氰基，硝基等，m为1或2，p为O，1或2，q为O或1.本发明还涉及式I的用途化合物，以治疗，预防或改善 对钙通道阻断，特别是N型钙通道的阻滞作用。 本发明的化合物特别适用于治疗疼痛。

    Nitrogen-containing heterocycle derivatives substituted with cyclic group
    5.
    发明授权
    Nitrogen-containing heterocycle derivatives substituted with cyclic group 失效
    用环状基团取代的含氮杂环衍生物

    公开(公告)号：US07935706B2

    公开(公告)日：2011-05-03

    申请号：US12278412

    申请日：2007-02-21

    申请人： Moriyasu Masui ,  Makoto Adachi ,  Hidenori Mikamiyama ,  Akira Matsumura ,  Naoki Tsuno

    发明人： Moriyasu Masui ,  Makoto Adachi ,  Hidenori Mikamiyama ,  Akira Matsumura ,  Naoki Tsuno

    IPC分类号： A61K31/497

    CPC分类号： C07D209/08 ,  C07D209/34 ,  C07D215/38 ,  C07D235/08 ,  C07D235/26 ,  C07D249/18 ,  C07D263/58 ,  C07D277/68 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

    摘要： It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

    摘要翻译： 发现由式（I）表示的含氮杂环衍生物特异性结合NR1 / NR2B的受体，并用作NR2B受体拮抗剂。 由下式表示的化合物：其中Z为N或CR1，A1为任选取代的含氮芳族单环基团，任选取代的含氮芳族稠合环基等，A2为芳族烃环基或 芳族杂环基，各自任选具有取代基，R 1，R 2，R a，R b，R c和R d各自独立地为氢，羟基等，w为2或3，t为1或2，X为 - （CR 3 R 4）m - ，-CO（CR 3 R 4）n - ， - CONR 5（CR 3 R 4）n - 等，m为1〜4的整数，n为0〜4的整数，R 3和R 4各自独立地为氢，卤素，羟基等 R5为氢或低级烷基，或其药学上可接受的盐或溶剂合物。

    HARD-COATED ANTIGLARE FILM, POLARIZING PLATE AND IMAGE DISPLAY INCLUDING THE SAME, METHOD FOR PRODUCING THE SAME, AND METHOD FOR EVALUATING THE SAME
    6.
    发明申请
    HARD-COATED ANTIGLARE FILM, POLARIZING PLATE AND IMAGE DISPLAY INCLUDING THE SAME, METHOD FOR PRODUCING THE SAME, AND METHOD FOR EVALUATING THE SAME 有权
    硬涂层防透膜，偏光板和包括其的图像显示器，其制造方法及其评估方法

    公开(公告)号：US20110080645A1

    公开(公告)日：2011-04-07

    申请号：US12900002

    申请日：2010-10-07

    申请人： Naoki Tsuno ,  Daisuke Hamamoto ,  Hiroki Kuramoto

    发明人： Naoki Tsuno ,  Daisuke Hamamoto ,  Hiroki Kuramoto

    IPC分类号： G02B5/02 ,  G02B1/10 ,  G02B1/04 ,  G01B11/30 ,  B05D5/06

    CPC分类号： G02B5/0278 ,  C08K3/22 ,  C08K3/36 ,  C08K9/08 ,  C09D7/62 ,  C09D7/67 ,  C09D7/68 ,  C09D133/12 ,  G02B1/105 ,  G02B1/11 ,  G02B1/118 ,  G02B1/14 ,  G02B5/0221 ,  G02B5/0242 ,  G02B5/0268 ,  G02B5/0294 ,  G02F1/133502 ,  C08K3/20

    摘要： A hard-coated antiglare film that has superior antiglare properties, allow high definition to be provided even in the case of a low haze value, can prevent white blur in an oblique direction from occurring and, and can improve the depth of black in black display, as well as a polarizing plate, and the like. The hard-coated antiglare film includes a transparent plastic film substrate and a hard-coating antiglare layer containing fine particles, which is on at least one surface of the transparent plastic film substrate. The hard-coated antiglare film has a total haze value Ht in the range of 10% to 35%. The total haze value Ht and an internal haze value Hin satisfy a relationship of 0.5≦Hin/Ht≦0.9. The surface of the hard-coating antiglare layer has an uneven shape and an arithmetic average surface roughness Ra in the range of 0.1 to 0.3 μm. The hard-coated antiglare film includes: convexities that exceed a roughness mean line of a surface roughness profile; no convexities in which line segments of portions of the mean line that cross the convexities each have a length of 80 μm or longer, and convexities that exceed a standard line that is in parallel with the mean line and is located at a height of 0.1 μm; and at least 50 convexities in which line segments of portions of the standard line that cross the convexities each have a length of 20 μm or shorter in 4-mm long portion at an arbitrary location of the surface of the hard-coating antiglare layer.

    摘要翻译： 具有优异防眩性的硬涂层防眩膜即使在低雾度值的情况下也能够提供高清晰度，可以防止发生倾斜方向的白色模糊，并且可以改善黑色显示中的黑色深度 ，以及偏振片等。 硬涂层的防眩膜包括透明塑料膜基材和在透明塑料膜基材的至少一个表面上的含有微粒的硬涂层防眩光层。 硬涂层防眩膜的总浊度值Ht在10％至35％的范围内。 总雾度值Ht和内部雾度值Hin满足0.5＆nlE; Hin / Ht＆nlE; 0.9的关系。 硬涂层防眩层的表面具有不均匀的形状和算术平均表面粗糙度Ra在0.1至0.3μm的范围内。 硬涂层防眩膜包括：超过表面粗糙度轮廓的粗糙度平均线的凸面; 平均线的横贯凸部的部分的线段各自具有80μm以上的长度的凸面和超过与平均线平行且位于0.1μm的高度的标准线的凸部 ; 以及至少50个凸部，其中在硬涂层防眩光层的表面的任意位置处，与凸部交叉的标准线的部分的线段各自在4mm长的部分中具有20μm或更短的长度。

    Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
    10.
    发明授权
    Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators 有权
    取代的喹喔啉型桥接哌啶化合物作为ORL-1调节剂

    公开(公告)号：US08476271B2

    公开(公告)日：2013-07-02

    申请号：US13010632

    申请日：2011-01-20

    申请人： Naoki Tsuno ,  Jiangchao Yao

    发明人： Naoki Tsuno ,  Jiangchao Yao

    IPC分类号： A61K31/495

    CPC分类号： C07D471/08 ,  C07D403/04 ,  C07D451/14

    摘要： Compounds of Formula (I): where R1, R2, R5, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof (a “Substituted-Quinoxaline-Type Bridged-Piperidine Compound”), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

    摘要翻译： 式（I）的化合物：其中R 1，R 2，R 5，a和b在此公开，及其药学上可接受的衍生物（“取代的喹喔啉型桥连哌啶化合物”），包含有效量的取代 - 喹喔啉型桥连哌啶化合物，以及治疗或预防诸如疼痛的病症的方法，包括向有需要的动物施用有效量的取代的喹喔啉型桥连哌啶化合物。